AstraZeneca licenses Zegfrovy from Dizal

AstraZeneca has entered into an exclusive global license agreement with Dizal Pharmaceutical Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. AstraZeneca will acquire worldwide rights to develop and commercialize Zegfrovy, which is already approved in the US and China for second-line treatment. Dizal Pharmaceutical will receive an upfront payment of $600 million, up to $900 million in milestone payments, and tiered royalties on global sales. The deal is expected to close in the second half of 2026. Dizal Pharmaceutical recently announced positive Phase III WU-KONG28 trial results in first-line NSCLC, supporting sNDA submissions to the FDA and China's CDE, both of which granted Breakthrough Therapy Designation.